Hackensack Meridian Health: Multiple Myeloma trials

The registry lists 16 Multiple Myeloma studies with Hackensack Meridian Health as lead sponsor. 2 are open to participants now and 11 have results posted.

Phase 1 8Phase 2 13Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 2
• Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple MyelomaRecruitingNCT03909412Phase 1
• Fluoroquinolone Resistance Prevalence StudyTerminatedNCT05824689Results posted
• A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple MyelomaTerminatedNCT04700176Phase 2Results posted
• Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)TerminatedNCT02906332Phase 2Results posted
• Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceTerminatedNCT02681302Phase 1/2Results posted
• Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing RegimensCompletedNCT01502085Phase 1/2Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01453101Phase 2Results posted
• Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or OlderTerminatedNCT01453088Phase 2Results posted
• Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCTCompletedNCT01242267Phase 1/2Results posted
• Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple MyelomaCompletedNCT01241708Phase 3Results posted
• Study Combining Bortezomib With High Dose Melphalan to Treat Multiple MyelomaCompletedNCT00784823Phase 1/2Results posted
• A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00464178Phase 2Results posted
• Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.WithdrawnNCT05493618Phase 1/2
• Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple MyelomaSuspendedNCT05199311Phase 1/2
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT01297764Phase 1/2